Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
993 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | completed | Phase 1 / Phase 2 | 53 | AbbVieINDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT02014129 | A Study of LY2835219 in Japanese Participants With Advanced Cancer | completed | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02658214 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors |
| completed |
| Phase 1 |
| 32 |
| AstraZenecaINDUSTRY |
| 2 |
| Aug 20, 2020 |
| clinicaltrials |
| NCT01832506 | A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors | completed | Phase 1 | 12 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT01049061 | A Study of MORAb-003 in Patients With Solid Tumor | completed | Phase 1 | 16 | Eisai Co., Ltd.INDUSTRY | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03235570 | A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) | completed | Phase 1 | 44 | Incyte CorporationINDUSTRY | 1 | May 29, 2020 | clinicaltrials |
| NCT02677116 | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | completed | Phase 1 | 68 | Eli Lilly and CompanyINDUSTRY | 2 | May 20, 2020 | clinicaltrials |
| NCT03027284 | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT02534506 | Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors | completed | Phase 1 | 18 | Bristol-Myers SquibbINDUSTRY | 1 | May 18, 2020 | clinicaltrials |
| NCT02162836 | A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 6 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Apr 27, 2020 | clinicaltrials |
| NCT02884726 | Phase 1 Study of Mesothelin-ADC | completed | Phase 1 | 8 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT02946671 | Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients | completed | Phase 1 | 16 | Osaka UniversityOTHER | 1 | Mar 6, 2020 | clinicaltrials |
| NCT03135028 | Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults(Japanese AML) | terminated | Phase 1 | 9 | Gilead SciencesINDUSTRY | 1 | Mar 6, 2020 | clinicaltrials |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | terminated | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 24, 2020 | clinicaltrials |
| NCT02240433 | A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT00555100 | Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma | completed | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01568294 | Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01763788 | A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 192 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02148549 | Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study(FIRINOX) | completed | Phase 1 | 10 | Wakayama Medical UniversityOTHER | 1 | Oct 7, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT01919398 | A Study of LY2940680 in Japanese Participants With Advanced Cancers | completed | Phase 1 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02999295 | A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer | completed | Phase 1 / Phase 2 | 46 | National Cancer Center, JapanOTHER_GOV | 1 | Aug 21, 2019 | clinicaltrials |
| NCT02556892 | A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 1 | 8 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02949895 | Study of BMS-986012 in Subjects With Small Cell Lung Caner | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT01055496 | Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | completed | Phase 1 | 103 | PfizerINDUSTRY | 9 | Aug 2, 2019 | clinicaltrials |
| NCT02613221 | A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer(APOLLON) | completed | Phase 1 / Phase 2 | 56 | TakedaINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00079430 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 113 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2019 | clinicaltrials |
| NCT02004717 | Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jul 22, 2019 | clinicaltrials |
| NCT03736473 | A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients | completed | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02367352 | Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | terminated | Phase 1 | 9 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 26, 2019 | clinicaltrials |
| NCT02047890 | Japanese BAY1000394 Monotherapy Phase I Study | completed | Phase 1 | 12 | BayerINDUSTRY | 1 | Jun 24, 2019 | clinicaltrials |
| NCT03394144 | Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 11 | AstraZenecaINDUSTRY | 1 | Jun 24, 2019 | clinicaltrials |
| NCT02476123 | Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors | completed | Phase 1 | 118 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 11, 2019 | clinicaltrials |
| NCT01962532 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 19 | Janssen Research & Development, LLCINDUSTRY | 1 | May 15, 2019 | clinicaltrials |
| NCT03192943 | A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors | completed | Phase 1 | 11 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 1, 2019 | clinicaltrials |
| NCT02341456 | Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | completed | Phase 1 | 19 | AstraZenecaINDUSTRY | 3 | Mar 25, 2019 | clinicaltrials |
| NCT01556438 | Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma | completed | Phase 1 | 16 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01069575 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 18 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01069640 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*02-positive Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 9 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01069653 | Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer | completed | Phase 1 | 9 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01949688 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01949701 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01950156 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02454478 | Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC) | completed | Phase 1 | 7 | Eisai Co., Ltd.INDUSTRY | 1 | Mar 19, 2019 | clinicaltrials |
| NCT00724971 | Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab | completed | Phase 1 | 10 | PfizerINDUSTRY | 1 | Mar 15, 2019 | clinicaltrials |
| NCT03311477 | A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors | completed | Phase 1 | 9 | AbbVieINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02497378 | A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Mar 7, 2019 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials